News
-
-
-
-
-
-
-
-
PRESS RELEASE
Press Release: Sanofi’s Cenrifki (tolebrutinib) approved in the EU as the first disability-targeting medicine for secondary progressive multiple sclerosis without relapses
Sanofi gains EU approval for Cenrifki (tolebrutinib) as the first disability-targeting medicine for secondary progressive multiple sclerosis without relapses, based on phase 3 studies. Cenrifki addresses SPMS disability progression -
-